Health
Ozempic Users Cut Grocery Spending by Up to 9%, Survey Finds
- Morgan Stanley says snacks and sweets most hurt by GLP-1s
- Report cites Numerator data from across 90,000 households
This article is for subscribers only.
There’s now data to justify the anxiety from snack-food makers about how appetite-suppressing weight-loss shots like Ozempic will hurt their business.
When monthly grocery spending is adjusted for factors including household size and income, spending in households that use so-called GLP-1 drugs decreased by 6% to 9% versus non-GLP-1 households, Morgan Stanley said in a report, citing a survey from Numerator, a market-research provider.